Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 256

1.

Genetic testing in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a cost-effectiveness analysis.

Lala A, Berger JS, Sharma G, Hochman JS, Scott Braithwaite R, Ladapo JA.

J Thromb Haemost. 2013 Jan;11(1):81-91. doi: 10.1111/jth.12059.

2.

CYP2C19 LOF and GOF-Guided Antiplatelet Therapy in Patients with Acute Coronary Syndrome: A Cost-Effectiveness Analysis.

Jiang M, You JH.

Cardiovasc Drugs Ther. 2017 Feb;31(1):39-49. doi: 10.1007/s10557-016-6705-y.

PMID:
27924429
3.

The cost effectiveness of genetic testing for CYP2C19 variants to guide thienopyridine treatment in patients with acute coronary syndromes: a New Zealand evaluation.

Panattoni L, Brown PM, Te Ao B, Webster M, Gladding P.

Pharmacoeconomics. 2012 Nov 1;30(11):1067-84. doi: 10.2165/11595080-000000000-00000.

PMID:
22974536
4.

Cost-effectiveness of genotype-guided and dual antiplatelet therapies in acute coronary syndrome.

Kazi DS, Garber AM, Shah RU, Dudley RA, Mell MW, Rhee C, Moshkevich S, Boothroyd DB, Owens DK, Hlatky MA.

Ann Intern Med. 2014 Feb 18;160(4):221-32.

PMID:
24727840
5.

Cost-effectiveness of cytochrome P450 2C19 genotype screening for selection of antiplatelet therapy with clopidogrel or prasugrel.

Reese ES, Daniel Mullins C, Beitelshees AL, Onukwugha E.

Pharmacotherapy. 2012 Apr;32(4):323-32. doi: 10.1002/j.1875-9114.2012.01048. Erratum in: Pharmacotherapy. 2012 Jun;32(6):581.

6.

Prasugrel compared to clopidogrel in patients with acute coronary syndrome undergoing percutenaous coronary intervention: a Spanish model-based cost effectiveness analysis.

Davies A, Sculpher M, Barrett A, Huete T, Sacristán JA, Dilla T.

Farm Hosp. 2013 Jul-Aug;37(4):307-16. doi: 10.7399/FH.2013.37.4.687.

7.

Prasugrel vs clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a model-based cost-effectiveness analysis for Germany, Sweden, the Netherlands, and Turkey.

Davies A, Bakhai A, Schmitt C, Barrett A, Graham-Clarke P, Sculpher M.

J Med Econ. 2013;16(4):510-21. doi: 10.3111/13696998.2013.768998. Epub 2013 Feb 12.

PMID:
23339464
9.

CYP2C19 genotype plus platelet reactivity-guided antiplatelet therapy in acute coronary syndrome patients: a decision analysis.

Jiang M, You JH.

Pharmacogenet Genomics. 2015 Dec;25(12):609-17. doi: 10.1097/FPC.0000000000000177.

PMID:
26398625
10.
11.

Review of pharmacoeconomic evaluation of genotype-guided antiplatelet therapy.

Jiang M, You JH.

Expert Opin Pharmacother. 2015 Apr;16(5):771-9. doi: 10.1517/14656566.2015.1013028. Epub 2015 Feb 7. Review.

PMID:
25660101
12.

Impact of CYP2C19 genetic testing on provider prescribing patterns for antiplatelet therapy after acute coronary syndromes and percutaneous coronary intervention.

Desai NR, Canestaro WJ, Kyrychenko P, Chaplin D, Martell LA, Brennan T, Matlin OS, Choudhry NK.

Circ Cardiovasc Qual Outcomes. 2013 Nov;6(6):694-9. doi: 10.1161/CIRCOUTCOMES.113.000321. Epub 2013 Nov 5.

13.

Cost-effectiveness of universal and platelet reactivity assay-driven antiplatelet therapy in acute coronary syndrome.

Coleman CI, Limone BL.

Am J Cardiol. 2013 Aug 1;112(3):355-62. doi: 10.1016/j.amjcard.2013.03.036. Epub 2013 Apr 27.

PMID:
23631863
14.

Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis.

Mega JL, Close SL, Wiviott SD, Shen L, Walker JR, Simon T, Antman EM, Braunwald E, Sabatine MS.

Lancet. 2010 Oct 16;376(9749):1312-9. doi: 10.1016/S0140-6736(10)61273-1.

15.

Prasugrel for the treatment of acute coronary artery syndromes with percutaneous coronary intervention.

Greenhalgh J, Bagust A, Boland A, Saborido CM, Fleeman N, McLeod C, Dundar Y, Dickson R, Proudlove C, Kolamunnage-Dona R, Fisher M.

Health Technol Assess. 2010 May;14 Suppl 1:31-8. doi: 10.3310/hta14Suppl1/05. Review.

16.

A risk-benefit assessment of prasugrel, clopidogrel, and genotype-guided therapy in patients undergoing percutaneous coronary intervention.

Guzauskas GF, Hughes DA, Bradley SM, Veenstra DL.

Clin Pharmacol Ther. 2012 May;91(5):829-37. doi: 10.1038/clpt.2011.303. Epub 2012 Mar 28.

PMID:
22453194
17.
18.

Cost-effectiveness of prasugrel in a US managed care population.

Mauskopf JA, Graham JB, Bae JP, Ramaswamy K, Zagar AJ, Magnuson EA, Cohen DJ, Meadows ES.

J Med Econ. 2012;15(1):166-74. doi: 10.3111/13696998.2011.637590. Epub 2011 Nov 18.

PMID:
22066985
19.

Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial.

Roberts JD, Wells GA, Le May MR, Labinaz M, Glover C, Froeschl M, Dick A, Marquis JF, O'Brien E, Goncalves S, Druce I, Stewart A, Gollob MH, So DY.

Lancet. 2012 May 5;379(9827):1705-11. doi: 10.1016/S0140-6736(12)60161-5. Epub 2012 Mar 29.

PMID:
22464343
20.

A model-based analysis of the clinical and economic impact of personalising P2Y12-receptor inhibition with platelet function testing in acute coronary syndrome patients.

Straub N, Beivers A, Lenk E, Aradi D, Sibbing D.

Thromb Haemost. 2014 Feb;111(2):290-9. doi: 10.1160/TH13-08-0679. Epub 2013 Oct 24.

PMID:
24154566

Supplemental Content

Support Center